Earnings Preview: Allergan

Allergan (AGN) is expected to report Q3 earnings on Thursday, October 29 before the market open with a conference call scheduled for 11am ET.

Guidance

Analysts are looking for EPS of 70c on revenue of $1.08B. The consensus range is 67c-72c for EPS, and $1.05B-$1.11B for revenue, according to First Call. Positive drivers for Q3 include the resiliency of Botox and the diverse product mix that Allergan has in the aesthetic market. Negative headwinds may come from currency translations, a poor economic environment for aesthetic procedures, and Botox competitor Dysport (MRX).

Analyst Views

On September 30, Allergan was initiated with a Buy at Canaccord and $71.50 target. On October 2, Collins Stewart said Allergan's lawsuit against the FDA and Department of Justice will not impact sales of Botox. The firm keeps a Hold rating on the stock.